Showing results (651-660 of 676) with videos related to

Sort By:
Pageof 68
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 25, 2021
The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?Alexander Marx, John K C Chan, Lara Chalabreysse, et al.
Journal of Thrombosis and Haemostasis : JTH|April 5, 2020
Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluationGuy Young, Anthonie W A Lensing, Paul Monagle, et al.
The American Journal of Pathology|February 27, 2007
Hypermethylation of RASSF1A in human and rhesus placentasRossa W K Chiu, Stephen S C Chim, Ivy H N Wong, et al.
European Journal of Haematology|July 13, 2023
Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A-Final efficacy and safety results from the NuProtect studyMary Mathias, Aby Abraham, Mark J Belletrutti, et al.
Cell Reports|August 14, 2020
A Three-Way Combinatorial CRISPR Screen for Analyzing Interactions among Druggable TargetsPeng Zhou, Becky K C Chan, Yuk Kei Wan, et al.
International Journal of Molecular Sciences|April 23, 2022
Diagnostic Value of MAML2 Rearrangements in Mucoepidermoid CarcinomaJulia C Thierauf, Alex A Farahani, B Iciar Indave, et al.
Thrombosis and Haemostasis|February 13, 2021
Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect StudyRi J Liesner, Aby Abraham, Carmen Altisent, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 18, 2017
Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect StudyR J Liesner, M Abashidze, O Aleinikova, et al.
Pageof 68